title: Homologous overexpression of RfaH in E. coli K4 improves the production of chondroitin-like capsular polysaccharide.
abstract: BACKGROUND
  Glycosaminoglycans, such as hyaluronic acid, heparin, and chondroitin sulfate, are among the top ranked products in industrial biotechnology for biomedical applications, with a growing world market of billion dollars per year. Recently a remarkable progress has been made in the development of tailor-made strains as sources for the manufacturing of such products. The genetic modification of E. coli K4, a natural producer of chondroitin sulfate precursor, is challenging considering the lack of detailed information on its genome, as well as its mobilome. Chondroitin sulfate is currently used as nutraceutical for the treatment of osteoarthritis, and several new therapeutic applications, spanning from the development of skin substitutes to live attenuated vaccines, are under evaluation.
  
  
  RESULTS
  E. coli K4 was used as host for the overexpression of RfaH, a positive regulator that controls expression of the polysaccharide biosynthesis genes and other genes necessary for the virulence of E. coli K4. Various engineering strategies were compared to investigate different types of expression systems (plasmid vs integrative cassettes) and integration sites (genome vs endogenous mobile element). All strains analysed in shake flasks on different media showed a capsular polysaccharide production improved by 40 to 140%, compared to the wild type, with respect to the final product titer. A DO-stat fed-batch process on the 2L scale was also developed for the best performing integrative strain, EcK4r3, yielding 5.3 g ∙ L(-1) of K4 polysaccharide. The effect of rfaH overexpression in EcK4r3 affected the production of lipopolysaccharide and the expression of genes involved in the polysaccharide biosynthesis pathway (kfoC and kfoA), as expected. An alteration of cellular metabolism was revealed by changes of intracellular pools of UDP-sugars which are used as precursors for polysaccharide biosynthesis.
  
  
  CONCLUSIONS
  The present study describes the identification of a gene target and the application of a successful metabolic engineering strategy to the unconventional host E. coli K4 demonstrating the feasibility of using the recombinant strain as stable cell factory for further process implementations.
authors: Department of Experimental Medicine, Section of Biotechnology and Molecular Biology, Second University of Naples, via de Crecchio 7, Naples 80138, Italy. donatella.cimini@unina2.it
authors: Donatella
authors: D
authors: Cimini
authors: Mario
authors: M
authors: De Rosa
authors: Elisabetta
authors: E
authors: Carlino
authors: Alessandro
authors: A
authors: Ruggiero
authors: Chiara
authors: C
authors: Schiraldi
mesh_terms: D061249:Batch Cell Culture Techniques; D018533:Biomass; D019149:Bioreactors; D002809:Chondroitin Sulfates / Q000096:biosynthesis; D004926:Escherichia coli / Q000378:metabolism*; D029968:Escherichia coli Proteins / Q000235:genetics / Q000378:metabolism*; D006868:Hydrolysis; D008070:Lipopolysaccharides / Q000096:biosynthesis; D060847:Metabolic Engineering; D053858:Metabolic Networks and Pathways; D010445:Peptide Elongation Factors / Q000235:genetics / Q000378:metabolism*; D010957:Plasmids / Q000235:genetics / Q000378:metabolism; D011134:Polysaccharides / Q000096:biosynthesis*; D015534:Trans-Activators / Q000235:genetics / Q000378:metabolism*
chemical_list: D029968:Escherichia coli Proteins; D008070:Lipopolysaccharides; D010445:Peptide Elongation Factors; D011134:Polysaccharides; C106401:RfaH protein, E coli; D015534:Trans-Activators; D002809:Chondroitin Sulfates
references: Biol Pharm Bull. 2010;33(3):410-4
references: 20190401
references: Mol Microbiol. 1997 Jun;24(5):1001-12
references: 9220007
references: Biomed Chromatogr. 1998 May-Jun;12(3):113-5
references: 9646903
references: Biotechnol J. 2012 Feb;7(2):237-50
references: 22125298
references: J Biochem. 2006 Oct;140(4):517-24
references: 16936295
references: J Bacteriol. 2000 May;182(10):2741-5
references: 10781541
references: Biotechnol Lett. 2008 Mar;30(3):493-6
references: 17957340
references: Mol Cell Proteomics. 2009 Oct;8(10):2321-38
references: 19508964
references: Biochemistry. 2008 Nov 25;47(47):12635-43
references: 18975976
references: Mol Microbiol. 1999 Mar;31(5):1307-19
references: 10200953
references: J Ind Microbiol Biotechnol. 2009 Nov;36(11):1337-44
references: 19626354
references: Appl Microbiol Biotechnol. 2012 Apr;94(2):295-305
references: 22391966
references: Mol Microbiol. 1990 Nov;4(11):1863-9
references: 2082146
references: Methods. 2001 Dec;25(4):402-8
references: 11846609
references: J Bacteriol. 1988 Mar;170(3):1305-10
references: 2830235
references: Infect Immun. 2002 Aug;70(8):4406-13
references: 12117951
references: Biotechnol Prog. 2012 Jul;28(4):1012-8
references: 22619212
references: Inflammopharmacology. 2011 Dec;19(6):299-306
references: 22042237
references: Electrophoresis. 2009 Nov;30(22):3877-83
references: 19938179
references: FEMS Microbiol Lett. 1994 Nov 15;124(1):93-8
references: 8001774
references: Anal Biochem. 2003 Feb 1;313(1):145-54
references: 12576070
references: Biomaterials. 2006 Nov;27(33):5689-97
references: 16908060
references: J Biol Chem. 2002 Jun 14;277(24):21567-75
references: 11943778
references: Appl Microbiol Biotechnol. 2010 Feb;85(6):1779-87
references: 19795118
references: Microb Cell Fact. 2011 Feb 16;10:10
references: 21324163
references: J Bacteriol. 1994 Feb;176(3):830-9
references: 8300536
references: J Bacteriol. 1998 Jun;180(12):3070-9
references: 9620955
references: J Biotechnol. 2010 Nov;150(3):324-31
references: 20888875
references: Angew Chem Int Ed Engl. 2011 Jun 27;50(27):6160-3
references: 21594958